Notification That Annual Report Will Be Submitted Late (nt 10-k)
28 Diciembre 2017 - 10:26AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
12b-25
SEC
File Number 000-25169
NOTIFICATION
OF LATE FILING
(Check
One)
: ☒Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form
N-SAR ☐ Form N-CSR
For
Period Ended:
September 30, 2017
☐
Transition Report on Form 10-K
☐
Transition Report on Form 20-F
☐
Transition Report on Form 11-K
☐
Transition Report on Form 10-Q
☐
Transition Report on Form N-SAR
For
the Transition Period Ended: ________________________
Nothing
in this form shall be construed to imply that the Commission has verified any information contained herein.
If the
notification relates to a portion of the filing checked above, identify the item(s) to which the notification relates:
PART
I -- REGISTRANT INFORMATION
Regen Biopharma, Inc.
|
|
Full Name of Registrant
|
|
|
|
|
|
Former Name of Registrant
|
|
|
|
4700 Spring Street, Suite 304
|
|
Address of Principal Executive Officer (Street and Number)
|
|
|
|
La Mesa, CA 91942
|
|
City, State and Zip Code
|
|
PART
II -- RULES 12b-25(b) AND (c)
If the
subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b),
the following should be completed. (Check box if appropriate.)
|
(a)
|
The
reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
|
☒
|
(b)
|
The subject
annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR,
or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or
the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof,
will be filed on or before the fifth calendar day following the prescribed due date; and
|
|
(c)
|
The accountant's
statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.
|
PART
III-- NARRATIVE
State
below in reasonable detail why the Form 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR or the transition report portion thereof, could
not be filed within the prescribed time period. (Attach extra sheets if needed.)
The
Company could not complete the filing of its Annual Report on Form 10-K for the period ended September 30, 2017 due
to a delay in preparation of the Company's Form 10-K, which delay could not be eliminated by the Company without unreasonable effort
and expense. In accordance with Rule 12b-25 of the Securities Exchange Act of 1934, as amended, the Company will file its Form
10-K no later than the fifteenth calendar day following the prescribed due date.
PART
IV -- OTHER INFORMATION
(1) Name
and telephone number of person to contact in regard to this notification
David Koos
|
|
(619)
|
|
702-1404
|
(Name)
|
|
(Area
Code)
|
|
(Telephone
Number)
|
(2)
Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the
Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file
such report(s) been filed? If the answer is no, identify report(s).
☒ Yes
☐ No
(3)
Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year
will be reflected by the earnings statements to be included in the subject report or portion thereof?
☐
Yes ☒ No
If
so: attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons
why a reasonable estimate of the results cannot be made.
Regen Biopharma, Inc.
(Name
of Registrant as Specified in Charter)
Has caused
this notification to be signed on its behalf by the undersigned thereunto duly authorized.
Date: December 28, 2017
|
By:
|
/s/ David Koos
|
|
|
David Koos
|
|
|
Chief Executive Officer
|
Regen Biopharma (PK) (USOTC:RGBPP)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Regen Biopharma (PK) (USOTC:RGBPP)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024